| Powder: | Yes |
|---|---|
| Customized: | Non-Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Elderly, Children, Adult |
| State: | Solid |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier Bortezomib was the first proteasome inhibitor to be used clinically. The proteasome is present in all eukaryotic cells and degrades over 80% of the proteins in the cell. It can reversibly inhibit the function of proteasome, thus inhibiting the Chemicalbook solution of protein, leading to protein accumulation and apoptosis. Because multiple myeloma (MM) continually replicates and secretes myeloma proteins, it is more sensitive to proteasomes than normal cells and can be used as a second-line treatment for MM and mantle cell lymphoma.
Bortezomib cannot be taken orally and requires frequent administration to maintain proteasome inhibition in vivo. Moreover, most tumors exhibit inherent resistance to bortezomib, and tumors sensitive to bortezomib eventually acquire resistance, resulting in poor treatment of solid tumors.
| Product Name | Bortezomib |
| Synonyms | Boronic acid, B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]bu;MG-341 PS-341;BortezoMib Base;BortezoMib-D8;bortezoMib(other);MLM341;BortezoMib R;VELCADE(BORTEZOMIB) |
| MOQ | 100g |
| CAS | 179324-69-7 |
| Appearance | White |
| Molecular Formula | C19H25BN4O4 |
| Molecular Weight | 384.24 |
| Assay | >99% |
| Application | For research purpose only |
| Packing | 5kg/drum |
| Storage | Store in a well-closed,light-resistant container |
| Remarks | NA |
| Custom synthesis | Available |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}